ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2295

A Pharmacometric Based Analysis of the Occurrence of Selected Safety Events of Special Interest and Canakinumab Exposure in Systemic Juvenile Idiopathic Arthritis Patients

Micha Levi1, Thomas Dumortier2, Nicolino Ruperto3, Hermine H. Brunner4 and Olivier Luttringer2, 1Novartis Pharmaceutical Corporation, East Hanover, NJ, 2Novartis Pharma AG, Basel, Switzerland, 3Pediatria II,, Istituto Giannina Gaslini, Genoa, Italy, 4Rheumatology, PRCSG-Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Systemic JIA and canakinumab

  • Tweet
  • Email
  • Print
Session Information

Session Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Systemic Juvenile Idiopathic Arthritis, Spondyloarthropathy and Miscellaneous Pediatric Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose

Canakinumab (CAN), a human, selective anti-interleukin-1β monoclonal antibody, has demonstrated rapid and sustained efficacy in systemic juvenile idiopathic arthritis (SJIA) patients,1and is approved in >30 countries including USA, EU, Canada, UK and Russia. Given the nature of the disease (pediatric population, rare condition), the phase III program only included limited placebo data. In such a context, the safety profile of CAN has been characterized via a model-based analysis of the dose-exposure-safety event relationship. The purpose of the study is to explore the relationship between CAN concentration and the occurrence of adverse events of special interest (ESI) and related laboratory abnormalities.

Methods

The analysis considered the open-label, part I of phase III trial wherein SJIA patients received CAN 4mg/kg (300 mg max.) every 4 weeks for a maximum of 8 consecutive doses (n=188). Individual CAN concentration time-profiles have been predicted for those patients, by combining the patients’ CAN and IL-1β concentration-time data and an established population PK model. This model is a PK-binding model parameterized in terms of clearance of drug and ligand (IL-1β), central and peripheral volume for the drug, interstitial flow rate, ligand production rate and binding affinity which has been developed using all the data available from the entire CAN program. The average serum CAN concentration (Cavg) was calculated from the concentration time profiles for each patient and dosing interval. In each dosing interval, Cavg were compared between patients with and without  the following safety events of special  interest: AEs of abdominal pain, cough, headache, infection, serious AE infection, pyrexia, and vomiting, as well as lab abnormalities of thrombocytopenia (>3XULN [upper limit normal]), leucopenia (≤0.8 XLLN [lower limit normal]), >20g/L decrease from baseline hemoglobin, neutropenia (<0.9 X LLN), transaminases elevation (>3XLLN), elevated total cholesterol (≥1.5XULN), triglycerides (≥5.7 mmol/L), and >25% decrease from baseline estimated glomerular filtration rate for 2 consecutive visits.

Results

For all adverse ESIs and related laboratory abnormalities, except neutropenia, Cavg was not different for patients who experienced an event compared with those who did not. The mean Cavg for patients with neutropenia was comparable to the 74thpercentile of those patients without neutropenia, however this higher Cavg was not found to be associated with more infection.

Conclusion

A pharmacometric based analysis in SJIA patients treated with a therapeutic dose of CAN, did not find, in the range of CAN exposure observed, any relationship between average CAN exposure and the occurrence of any safety ESI, except for neutropenia. This increased Cavg in patients with neutropenia was not associated with increased infections. These data support the effective and safe use of CAN4mg/kg every 4 week for the treatment of SJIA in patients >2 years old.

 1Ruperto N. et al. N Engl J Med 2012; 367 (25):2396-406


Disclosure:

M. Levi,

Novartis Pharmaceutical Corporation,

3;

T. Dumortier,

Novartis,

3,

Novartis ,

1;

N. Ruperto,

Gaslini Hospital: Abbott, Astrazeneca, BMS, Centocor Research & Development, Eli Lilly and Company,

2,

Astrazeneca, Bristol Myers and Squibb, Janssen Biologics B.V., Roche, Wyeth/Pfizer,

8;

H. H. Brunner,

Novartis, Roche, BMS, Pfizer, Biogen, Boehringer-Ingelheim, Jannsen, Astrazeneca,

5,

Roche, Novartis,

8;

O. Luttringer,

Novartis ,

3.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-pharmacometric-based-analysis-of-the-occurrence-of-selected-safety-events-of-special-interest-and-canakinumab-exposure-in-systemic-juvenile-idiopathic-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies